Combining mesenchymal stem cell sheets with platelet-rich plasma gel/calcium phosphate particles: a novel strategy to promote bone regeneration

Qi, Yiying; Niu, Lie; Zhao, Tengfei; Shi, Zhijun; Di, Tuoyu; Feng, Gang; Li, Junhua; Huang, Zhongming

doi:10.1186/s13287-015-0256-1

Cited by 56 publications

(45 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Qi et al (38) also found that stem cell sheet transplantation promoted bone formation in a rat tibia osteotomy model. Meanwhile, the BMSC sheet exhibited a marked positive effect on bone regeneration in a rat femoral osteotomy model (43).…”

Section: Discussionmentioning

confidence: 99%

IGFBP7 regulates the osteogenic differentiation of bone marrow‐derived mesenchymal stem cellsviaWnt/β‐catenin signaling pathway

Zhang

Chen

et al. 2018

FASEB j.

Self Cite

View full text Add to dashboard Cite

Insulin-like growth factor-binding protein 7 (IGFBP7), a low-affinity IGF binder, may play an important role in bone metabolism. However, its function in osteogenic differentiation of human bone marrow-derived mesenchymal stem cells (BMSCs) remains unclear. Therefore, we investigated its effects on osteogenic differentiation. Overexpression of IGFBP7 enhanced the expression of osteo-specific genes and proteins, and IGFBP7 knockdown decreased osteogenesis-specific markers. More mineral deposits and higher alkaline phosphatase activity were observed after the up-regulation of IGFBP7. Moreover, β-catenin levels were up-regulated by the overexpression of IGFBP7 or the addition of extracellular IGFBP7 protein and were reduced by the depletion of IGFBP7. The increase in osteogenic differentiation due to the overexpression of IGFBP7 was partially decreased by specific Wnt/β-catenin signaling inhibitors. Using a rat tibial osteotomy model, a sheet of IGFBP7-overexpressing BMSCs improved bone healing, as demonstrated by imaging, biomechanical, and histologic analyses. Taken together, these findings indicate that IGFBP7 regulates the osteogenic differentiation of BMSCs partly via the Wnt/β-catenin signaling pathway.-Zhang, W., Chen, E., Chen, M., Ye, C., Qi, Y., Ding, Q., Li, H., Xue, D., Gao, X., Pan, Z. IGFBP7 regulates the osteogenic differentiation of bone marrow-derived mesenchymal stem cells via Wnt/β-catenin signaling pathway.

show abstract

Section: Discussionmentioning

confidence: 99%

IGFBP7 regulates the osteogenic differentiation of bone marrow‐derived mesenchymal stem cellsviaWnt/β‐catenin signaling pathway

Zhang

Chen

et al. 2018

FASEB j.

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition, the concentrated growth factors in PRP increase revascularization, promote mesenchymal stem cell and osteoblast development into osteocytes, and encourage granulation tissue formation to fill the defect. 107,108 PRP treatment for osteomyelitis in preclinical animal models A rabbit model of MRSA tibial bone infection has been used to determine the efficacy of L-PRP gel implanted into the infected bone. Six weeks after debridement, antibacterial efficacy and new bone formation were measured.…”

Section: Possible Mechanisms Of Prp Treatment For Osteomyelitismentioning

confidence: 99%

Platelet-Rich Plasma for the Treatment of Tissue Infection: Preparation and Clinical Evaluation

Zhang

Guo

Kuss

et al. 2019

Tissue Engineering Part B: Reviews

View full text Add to dashboard Cite

The management and treatment of tissue infection, especially chronic infection, represents a significant challenge. Application of autologous platelet-rich plasma (PRP) has emerged as a promising adjunct therapy for facilitating the healing of surgical wounds and tissue injuries. PRP is extracted from whole blood using a sequential centrifugation technique and when activated, can release a vast array of antimicrobial proteins, cytokines, and growth factors. These bioactive molecules are responsible for the ability of PRP to kill pathogens, resolve necrotic tissue, and promote wound healing. PRP is emerging as a useful supplement to prevent postoperative infection and treat chronic wound or bone infections. PRP displays a synergistic effect with antibiotics, which provides unique advantages when treating antibiotic-resistant bacteria. This review will describe the method for PRP preparation and its antibacterial properties, as well as discuss both preclinical in vivo results and evidence from clinical practice of PRP use for the treatment of wound and bone infections.

show abstract

“…Recent animal data confirm that the combination of MSCs with platelet-rich plasma most efficiently promoted bone regeneration in the presence of high calcium levels [30]. In addition to these direct, pro-regenerative and tissue reconstructive approaches, immunomodulatory intervention strategies have been reported to maximize regenerative and minimize destructive effects of inflammation leading to enhanced bone fracture healing in animal experiments [31,32,33].…”

Section: Introductionmentioning

confidence: 99%

Manufacturing of Human Extracellular Vesicle-Based Therapeutics for Clinical Use

Gimona

Pachler

Laner-Plamberger

et al. 2017

IJMS

255

192

View full text Add to dashboard Cite

Extracellular vesicles (EVs) derived from stem and progenitor cells may have therapeutic effects comparable to their parental cells and are considered promising agents for the treatment of a variety of diseases. To this end, strategies must be designed to successfully translate EV research and to develop safe and efficacious therapies, whilst taking into account the applicable regulations. Here, we discuss the requirements for manufacturing, safety, and efficacy testing of EVs along their path from the laboratory to the patient. Development of EV-therapeutics is influenced by the source cell types and the target diseases. In this article, we express our view based on our experience in manufacturing biological therapeutics for routine use or clinical testing, and focus on strategies for advancing mesenchymal stromal cell (MSC)-derived EV-based therapies. We also discuss the rationale for testing MSC-EVs in selected diseases with an unmet clinical need such as critical size bone defects, epidermolysis bullosa and spinal cord injury. While the scientific community, pharmaceutical companies and clinicians are at the point of entering into clinical trials for testing the therapeutic potential of various EV-based products, the identification of the mode of action underlying the suggested potency in each therapeutic approach remains a major challenge to the translational path.

show abstract

Combining mesenchymal stem cell sheets with platelet-rich plasma gel/calcium phosphate particles: a novel strategy to promote bone regeneration

Cited by 56 publications

References 45 publications

IGFBP7 regulates the osteogenic differentiation of bone marrow‐derived mesenchymal stem cellsviaWnt/β‐catenin signaling pathway

IGFBP7 regulates the osteogenic differentiation of bone marrow‐derived mesenchymal stem cellsviaWnt/β‐catenin signaling pathway

Platelet-Rich Plasma for the Treatment of Tissue Infection: Preparation and Clinical Evaluation

Manufacturing of Human Extracellular Vesicle-Based Therapeutics for Clinical Use

Contact Info

Product

Resources

About